Gsk (GSK) Cost of Revenue (2009 - 2026)

Gsk (GSK) has 18 years of Cost of Revenue data on file, last reported at $5.6 billion in Q3 2026.

• For the quarter ending Q3 2026, Cost of Revenue changed N/A year-over-year to $5.6 billion; the trailing twelve-month figure through Sep 2026 stood at $23.1 billion (changed N/A YoY), and the FY2025 full-year result was $12.0 billion, up 3.7% from the prior year.
• Cost of Revenue was $5.6 billion for Q3 2026 at Gsk, up from $3.0 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $12.0 billion in Q4 2025 to a low of $2.4 billion in Q1 2023.
• A 5-year average of $4.7 billion and a median of $2.9 billion in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 147.27% in 2022 and tumbled 35.22% in 2023, its largest moves.
• Gsk's Cost of Revenue stood at $11.2 billion in 2022, then decreased by 5.14% to $10.6 billion in 2023, then grew by 9.24% to $11.6 billion in 2024, then climbed by 3.28% to $12.0 billion in 2025, then tumbled by 53.64% to $5.6 billion in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $5.6 billion in Q3 2026, $3.0 billion in Q2 2026, and $2.5 billion in Q1 2026.